학술논문

Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing
Document Type
article
Source
Cancer. 128(4)
Subject
Health Services and Systems
Biomedical and Clinical Sciences
Health Sciences
Oncology and Carcinogenesis
Clinical Research
Cancer
Kidney Disease
Genetics
2.1 Biological and endogenous factors
Aetiology
Carcinoma
Renal Cell
Female
Fumarate Hydratase
Germ Cells
Germ-Line Mutation
Humans
Kidney Neoplasms
Leiomyomatosis
Neoplastic Syndromes
Hereditary
Prevalence
Skin Neoplasms
Uterine Neoplasms
fumarate hydratase
genetic testing
hereditary leiomyomatosis and renal cell cancer
kidney neoplasms
Public Health and Health Services
Oncology & Carcinogenesis
Oncology and carcinogenesis
Public health
Language
Abstract
BackgroundGermline variants in fumarate hydratase (FH) are associated with autosomal dominant (AD) hereditary leiomyomatosis and renal cell cancer (HLRCC) and autosomal recessive (AR) fumarase deficiency (FMRD). The prevalence and cancer penetrance across different FH variants remain unclear.MethodsA database containing 120,061 records from individuals undergoing cancer germline testing was obtained. FH variants were classified into 3 categories: AD HLRCC variants, AR FMRD variants, and variants of unknown significance (VUSs). Individuals with variants from these categories were compared with those with negative genetic testing.ResultsFH variants were detected in 1.3% of individuals (AD HLRCC, 0.3%; AR FMRD, 0.4%; VUS, 0.6%). The rate of AD HLRCC variants discovered among reportedly asymptomatic individuals without a clear indication for HLRCC testing was 1 in 2668 (0.04%). In comparison with those with negative genetic testing, the renal cell carcinoma (RCC) prevalence was elevated with AD HLRCC variants (17.0% vs 4.5%; P